Department of Healthcare Epidemiology, School of Public Health in the Graduate School of Medicine, Kyoto University, Yoshida Konoe-cho, Sakyo-ku, Kyoto, 606-8501, Japan.
Section of Clinical Epidemiology, Department of Community Medicine, Graduate School of Medicine, Kyoto University, 54 Kawahara-cho, Syogoin, Sakyo-ku, Kyoto, 606-8507, Japan.
J Gastroenterol. 2020 Jul;55(7):712-721. doi: 10.1007/s00535-020-01683-x. Epub 2020 Apr 3.
Only a few studies have longitudinally evaluated whether fatty pancreas increases the risk of type-2 diabetes (T2D), and their results were inconsistent. Fatty pancreas is closely linked to overweight and obesity, but previous studies did not exclude overweight or obese individuals. Therefore, in this cohort study, we investigated the association between fatty pancreas and T2D incidence in lean individuals.
Between 2008 and 2013, 1478 nondiabetic lean individuals (i.e. body-mass index < 25 kg/m) underwent health examinations including computed tomography (CT) and were followed for a median of 6.19 years. Fatty pancreas was evaluated by a histologically-validated method using pancreas attenuation (Hounsfield units [HU]) on CT at baseline; lower pancreas attenuation indicates more pancreatic fat. To detect incident T2D, we used fasting plasma glucose, HbA1c, and self-reports of prescribed anti-diabetes medications. Odds ratios (OR) for the association between pancreas attenuation and incident T2D were estimated using logistic regression models adjusted for likely confounders.
T2D occurred in 61 participants (4.13%) during the follow-up period. Lower pancreas attenuation (i.e. more pancreatic fat) at baseline was associated with incident T2D (unadjusted OR per 10 HU lower attenuation: 1.56 [95% CI 1.28-1.91], p < 0.001). The multivariable-adjusted analysis revealed a similar association (adjusted OR per 10 HU lower attenuation: 1.32 [95% CI 1.06-1.63], p = 0.012).
T2D was likely to develop in lean individuals with the fatty pancreas. Among people who are neither obese nor overweight, the fatty pancreas can be used to define a group at high risk for T2D.
仅有少数研究纵向评估了胰腺脂肪含量增加是否会增加 2 型糖尿病(T2D)的风险,且其结果并不一致。胰腺脂肪含量与超重和肥胖密切相关,但之前的研究并未排除超重或肥胖人群。因此,在这项队列研究中,我们在瘦人群体中调查了胰腺脂肪含量与 T2D 发病率之间的关系。
在 2008 年至 2013 年间,1478 名非糖尿病瘦个体(即 BMI<25 kg/m)接受了健康检查,包括计算机断层扫描(CT),并随访了中位数为 6.19 年。基线时通过 CT 上的胰腺衰减(Hounsfield 单位 [HU])进行组织学验证方法评估胰腺脂肪含量;较低的胰腺衰减表示更多的胰腺脂肪。为了检测 T2D 的发生,我们使用空腹血糖、HbA1c 和自我报告的处方抗糖尿病药物。使用逻辑回归模型调整可能的混杂因素后,估计胰腺衰减与 T2D 发生之间的比值比(OR)。
在随访期间,61 名参与者(4.13%)发生了 T2D。基线时较低的胰腺衰减(即更多的胰腺脂肪)与 T2D 的发生相关(未经调整的每 10 HU 衰减降低的 OR:1.56[95%CI 1.28-1.91],p<0.001)。多变量调整分析显示出类似的关联(调整后的每 10 HU 衰减降低的 OR:1.32[95%CI 1.06-1.63],p=0.012)。
T2D 可能发生在患有胰腺脂肪的瘦个体中。在既不肥胖也不超重的人群中,胰腺脂肪含量可用于定义 T2D 风险较高的人群。